Bispecific Antibody Platform: A Novel Asymmetrical Structure For Therapeutic Antibodies

Bispecific antibodies (bsAb) stand for an emerging class of next-generation antibody therapy. The innovative dual-specificity of bsAb opens up a wide range of applications to meet the current unmet needs of patients. Due to the complexity of controlling advanced biotherapeutics, the industry is still facing several challenges: difficulty in maintaining the affinity of the parental mAbs and poor manufacturability. As bsAbs comprises two distinct heavy and light chains, multiple final forms can arise during their assembly. The mispairing of heavy and light chains could lead to unwanted impurities that are difficult to remove due to their similarity to the desirable form. Herein, we introduce a Samsung Biologics proprietary bispecific antibody platform (SBL9), which enables strongly orthogonal pairing of heavy and light chains to ensure the desired formation of multiple chains. Notably, SBL9 preserves high thermo-stability and good manufacturability without any loss of affinity compared to the parental monoclonal antibodies.